|
AU2003281969B2
(en)
|
2002-11-18 |
2011-01-27 |
Roche Innovation Center Copenhagen A/S |
Amino-LNA, thio-LNA and alpha-L-oxy-LN
|
|
EP2379084B1
(en)
|
2008-10-15 |
2017-11-22 |
Ionis Pharmaceuticals, Inc. |
Modulation of factor 11 expression
|
|
EP2370451B1
(en)
|
2008-12-02 |
2016-11-16 |
Wave Life Sciences Japan, Inc. |
Method for the synthesis of phosphorus atom modified nucleic acids
|
|
KR101885383B1
(ko)
|
2009-07-06 |
2018-08-03 |
웨이브 라이프 사이언시스 리미티드 |
신규한 핵산 프로드러그 및 그의 사용 방법
|
|
US10428019B2
(en)
|
2010-09-24 |
2019-10-01 |
Wave Life Sciences Ltd. |
Chiral auxiliaries
|
|
CA2817960C
(en)
|
2010-11-17 |
2020-06-09 |
Isis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
|
EP2734208B1
(en)
|
2011-07-19 |
2017-03-01 |
Wave Life Sciences Ltd. |
Methods for the synthesis of functionalized nucleic acids
|
|
CA2848753C
(en)
|
2011-09-14 |
2022-07-26 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
|
US10174323B2
(en)
|
2012-05-16 |
2019-01-08 |
The General Hospital Corporation |
Compositions and methods for modulating ATP2A2 expression
|
|
AU2013262709A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
US10059941B2
(en)
|
2012-05-16 |
2018-08-28 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
EA201492122A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии utrn
|
|
EP2850188A4
(en)
|
2012-05-16 |
2016-01-20 |
Rana Therapeutics Inc |
COMPOSITIONS AND METHOD FOR MODULATING THE EXPRESSION OF THE HEMOGLOBIN GENE FAMILIES
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
PL2872485T3
(pl)
|
2012-07-13 |
2021-05-31 |
Wave Life Sciences Ltd. |
Asymetryczna grupa pomocnicza
|
|
CN104661664B
(zh)
|
2012-07-13 |
2020-07-03 |
波涛生命科学有限公司 |
手性控制
|
|
AU2013315225B2
(en)
|
2012-09-14 |
2018-11-08 |
Translate Bio Ma, Inc. |
Multimeric oligonucleotide compounds
|
|
CN117126846A
(zh)
|
2012-11-15 |
2023-11-28 |
罗氏创新中心哥本哈根有限公司 |
寡核苷酸缀合物
|
|
CA2893801A1
(en)
*
|
2013-01-30 |
2014-08-07 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotide carbohydrate conjugates
|
|
TWI680767B
(zh)
|
2013-05-01 |
2020-01-01 |
美商雷格勒斯治療公司 |
用於增強的細胞攝取之化合物及方法
|
|
DK2991656T3
(da)
|
2013-05-01 |
2020-03-23 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
|
|
SG11201508925WA
(en)
|
2013-05-01 |
2015-11-27 |
Regulus Therapeutics Inc |
Microrna compounds and methods for modulating mir-122
|
|
WO2015042447A1
(en)
|
2013-09-20 |
2015-03-26 |
Isis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
EP3060664B1
(en)
|
2013-10-25 |
2021-07-07 |
Sanofi |
Microrna compounds and methods for modulating mir-21 activity
|
|
WO2015108047A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
|
JPWO2015108048A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
|
EP4137572A1
(en)
|
2014-01-16 |
2023-02-22 |
Wave Life Sciences Ltd. |
Chiral design
|
|
WO2015113922A1
(en)
*
|
2014-01-30 |
2015-08-06 |
Roche Innovation Center Copenhagen A/S |
Poly oligomer compound with biocleavable conjugates
|
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
|
RU2019130898A
(ru)
|
2014-03-19 |
2019-11-11 |
Ионис Фармасьютикалз, Инк. |
Композиции для модуляции экспрессии атаксина 2
|
|
SG10201910844SA
(en)
|
2014-04-01 |
2020-01-30 |
Biogen Ma Inc |
Compositions for modulating sod-1 expression
|
|
KR20200102553A
(ko)
|
2014-05-01 |
2020-08-31 |
아이오니스 파마수티컬즈, 인코포레이티드 |
성장 호르몬 수용체 발현을 조절하기 위한 조성물 및 방법
|
|
DK3137596T3
(da)
|
2014-05-01 |
2019-09-02 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulation af komplement faktor b-ekspression
|
|
WO2015168532A2
(en)
|
2014-05-01 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating pkk expression
|
|
AU2015252895B2
(en)
|
2014-05-01 |
2021-07-15 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating angiopoietin-like 3 expression
|
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
|
BR112017001931A2
(pt)
|
2014-08-07 |
2017-11-28 |
Regulus Therapeutics Inc |
direcionamento de micrornas para distúrbios metabólicos
|
|
BR112017004056A2
(pt)
|
2014-09-12 |
2017-12-05 |
Biogen Ma Inc |
composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
|
|
CA2961993A1
(en)
|
2014-10-10 |
2016-04-14 |
F. Hoffmann-La Roche Ag |
Galnac phosphoramidites, nucleic acid conjugates thereof and their use
|
|
CA2967184A1
(en)
*
|
2014-11-10 |
2016-05-19 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination long acting compositions and methods for hepatitis c
|
|
WO2016096938A1
(en)
|
2014-12-16 |
2016-06-23 |
Roche Innovation Center Copenhagen A/S |
Chiral toxicity screening method
|
|
AU2015364508A1
(en)
|
2014-12-18 |
2017-07-06 |
Alnylam Pharmaceuticals, Inc. |
ReversirTM compounds
|
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
WO2016115490A1
(en)
|
2015-01-16 |
2016-07-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of dux4
|
|
US10758558B2
(en)
|
2015-02-13 |
2020-09-01 |
Translate Bio Ma, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
CN107429250B
(zh)
|
2015-04-03 |
2022-03-01 |
Ionis制药公司 |
用于调节tmprss6表达的化合物和方法
|
|
WO2016161374A1
(en)
|
2015-04-03 |
2016-10-06 |
University Of Massachusetts |
Oligonucleotide compounds for targeting huntingtin mrna
|
|
WO2016161378A1
(en)
|
2015-04-03 |
2016-10-06 |
University Of Massachusetts |
Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
|
|
EP3277811B1
(en)
|
2015-04-03 |
2020-12-23 |
University of Massachusetts |
Fully stabilized asymmetric sirna
|
|
US10407678B2
(en)
|
2015-04-16 |
2019-09-10 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
|
US10633653B2
(en)
|
2015-08-14 |
2020-04-28 |
University Of Massachusetts |
Bioactive conjugates for oligonucleotide delivery
|
|
JP6835826B2
(ja)
*
|
2015-08-24 |
2021-02-24 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Ｌｎａ−ｇプロセス
|
|
US20210052631A1
(en)
*
|
2015-09-25 |
2021-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
US10577388B2
(en)
|
2015-10-02 |
2020-03-03 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugation process
|
|
KR20180056766A
(ko)
|
2015-10-09 |
2018-05-29 |
웨이브 라이프 사이언시스 리미티드 |
뉴클레오티드 조성물 및 이의 방법
|
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
|
CA2999341A1
(en)
|
2015-11-06 |
2017-05-11 |
Ionis Pharmaceuticals, Inc. |
Modulating apolipoprotein (a) expression
|
|
DK4119569T3
(da)
*
|
2015-11-06 |
2024-08-12 |
Ionis Pharmaceuticals Inc |
Konjugerede antisense-forbindelser til anvendelse i behandling
|
|
HRP20210227T1
(hr)
|
2015-11-12 |
2021-03-19 |
F. Hoffmann - La Roche Ag |
Oligonukleotidi za indukciju ekspresije paternalnog gena ube3a
|
|
WO2017096395A1
(en)
|
2015-12-04 |
2017-06-08 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
|
CA3006015A1
(en)
|
2015-12-31 |
2017-07-06 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing ataxin-2 expression
|
|
AU2017205462A1
(en)
|
2016-01-05 |
2018-06-07 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing LRRK2 expression
|
|
ES2858090T3
(es)
*
|
2016-01-29 |
2021-09-29 |
Kyowa Kirin Co Ltd |
Complejo de ácidos nucleicos
|
|
WO2017132669A1
(en)
|
2016-01-31 |
2017-08-03 |
University Of Massachusetts |
Branched oligonucleotides
|
|
CA3011946A1
(en)
|
2016-03-07 |
2017-09-14 |
Arrowhead Pharmaceuticals, Inc. |
Targeting ligands for therapeutic compounds
|
|
CN114736901B
(zh)
|
2016-03-14 |
2024-05-31 |
豪夫迈·罗氏有限公司 |
用于减少pd-l1表达的寡核苷酸
|
|
AU2017234678A1
(en)
|
2016-03-16 |
2018-08-16 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating KEAP1
|
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
|
EP3228326A1
(en)
*
|
2016-04-05 |
2017-10-11 |
Silence Therapeutics GmbH |
Nucleic acid linked to a trivalent glycoconjugate
|
|
CA3020343A1
(en)
*
|
2016-04-08 |
2017-10-12 |
Translate Bio, Inc. |
Multimeric coding nucleic acid and uses thereof
|
|
WO2017178656A1
(en)
|
2016-04-14 |
2017-10-19 |
Roche Innovation Center Copenhagen A/S |
TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
|
|
CN109475568A
(zh)
|
2016-05-06 |
2019-03-15 |
Ionis制药公司 |
Glp-1受体配体部分缀合的寡核苷酸及其用途
|
|
CA3023514A1
(en)
|
2016-06-17 |
2017-12-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
|
MA45496A
(fr)
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
|
EP3475424A1
(en)
|
2016-06-22 |
2019-05-01 |
ProQR Therapeutics II B.V. |
Single-stranded rna-editing oligonucleotides
|
|
MA45620A
(fr)
|
2016-07-01 |
2019-05-08 |
Hoffmann La Roche |
Oligonucléotides antisens pour la modulation de l'expression de htra1
|
|
US11753638B2
(en)
|
2016-08-12 |
2023-09-12 |
University Of Massachusetts |
Conjugated oligonucleotides
|
|
DK3507366T3
(da)
|
2016-09-01 |
2020-11-02 |
Proqr Therapeutics Ii Bv |
Kemisk modificeret, enkeltstrengede rna-modificerende oligonukleotider
|
|
KR102403408B1
(ko)
|
2016-09-02 |
2022-05-30 |
애로우헤드 파마슈티컬스 인코포레이티드 |
표적화 리간드
|
|
WO2018067900A1
(en)
|
2016-10-06 |
2018-04-12 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
WO2018102745A1
(en)
|
2016-12-02 |
2018-06-07 |
Cold Spring Harbor Laboratory |
Modulation of lnc05 expression
|
|
US20190367920A1
(en)
|
2017-01-13 |
2019-12-05 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb1 expression
|
|
US20190345495A1
(en)
|
2017-01-13 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb2 expression
|
|
WO2018130581A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rela expression
|
|
WO2018130585A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating relb expression
|
|
WO2018130582A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rel expression
|
|
US11963974B2
(en)
|
2017-03-10 |
2024-04-23 |
National Center For Child Health And Development |
Antisense oligonucleotide and composition for prevention or treatment of glycogen storage disease type Ia
|
|
US11512312B2
(en)
|
2017-03-10 |
2022-11-29 |
The Board Of Regents Of The University Of Texas System |
Treatment of Fuchs' endothelial corneal dystrophy
|
|
KR20250145702A
(ko)
|
2017-04-11 |
2025-10-13 |
아뷰터스 바이오파마 코포레이션 |
표적화 조성물
|
|
WO2018215049A1
(en)
|
2017-05-23 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Process for galnac oligonucleotide conjugates
|
|
US11273222B2
(en)
|
2017-05-26 |
2022-03-15 |
National Cerebral And Cardiovascular Center |
Antisense nucleic acid targeting PCSK9
|
|
US20190055564A1
(en)
|
2017-06-01 |
2019-02-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
|
TW201908483A
(zh)
*
|
2017-06-02 |
2019-03-01 |
新加坡商波濤生命科學有限公司 |
寡核苷酸組合物及其使用方法
|
|
EP3599844A4
(en)
*
|
2017-06-07 |
2021-01-13 |
University of Massachusetts |
ANTI-ADAM33 OLIGONUCLEOTIDES AND RELATED PROCESSES
|
|
CN110799647A
(zh)
|
2017-06-23 |
2020-02-14 |
马萨诸塞大学 |
双尾自递送sirna及相关的方法
|
|
EP3668600B1
(en)
|
2017-08-10 |
2024-05-15 |
Abionyx Pharma SA |
Cargomers
|
|
WO2019030313A2
(en)
|
2017-08-11 |
2019-02-14 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
|
|
CA3073213A1
(en)
|
2017-08-17 |
2019-02-21 |
Alnylam Pharmaceuticals, Inc. |
Tunable reversir tm compounds
|
|
CA3071033A1
(en)
|
2017-08-18 |
2019-02-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
|
WO2019038228A1
(en)
|
2017-08-22 |
2019-02-28 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
|
|
WO2019051173A1
(en)
|
2017-09-08 |
2019-03-14 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF SMAD7 EXPRESSION
|
|
JP2020537518A
(ja)
|
2017-10-12 |
2020-12-24 |
ウェーブ ライフ サイエンシーズ リミテッド |
オリゴヌクレオチド組成物及びその方法
|
|
WO2019073018A1
(en)
|
2017-10-13 |
2019-04-18 |
Roche Innovation Center Copenhagen A/S |
METHODS OF IDENTIFYING ANTISENSE OLIGONUCLEOTIDE IMPROVED OLIGONUCLEOTIDE PHOSPHOROTHIOATE STEREODEFINIS VARIANTS USING PARTIALLY STEREODEFINIS OLIGONUCLEOTIDE SUB LIBRARIES
|
|
KR102431353B1
(ko)
|
2017-10-16 |
2022-08-10 |
에프. 호프만-라 로슈 아게 |
B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자
|
|
WO2019090359A1
(en)
|
2017-11-06 |
2019-05-09 |
Nitto Denko Corporation |
Fusogenic compounds for delivery of biologically active molecules
|
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
|
WO2019105419A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
EP3719125B1
(en)
|
2017-12-01 |
2025-01-08 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing same, and preparation method and use
|
|
US11414661B2
(en)
|
2017-12-01 |
2022-08-16 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
|
|
CA3083968C
(en)
|
2017-12-01 |
2024-04-23 |
Suzhou Ribo Life Science Co., Ltd. |
Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
|
|
EP3718572B1
(en)
|
2017-12-01 |
2024-07-31 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use
|
|
EP3720448A4
(en)
|
2017-12-06 |
2021-11-03 |
Avidity Biosciences, Inc. |
COMPOSITIONS AND METHODS OF TREATMENT OF MUSCLE ATROPHY AND MYOTONIC DYSTROPHY
|
|
EP3724333A2
(en)
|
2017-12-11 |
2020-10-21 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating fndc3b expression
|
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
|
US11459564B2
(en)
|
2017-12-21 |
2022-10-04 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
JP2021507253A
(ja)
|
2017-12-21 |
2021-02-22 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｈｔｒａ１ ｒｎａアンタゴニストについてのコンパニオン診断
|
|
EP3728592B1
(en)
|
2017-12-22 |
2024-05-29 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
|
JP7476101B2
(ja)
|
2017-12-22 |
2024-04-30 |
ロシュ イノベーション センター コペンハーゲン エーエス |
ホスホロジチオアートヌクレオシド間結合を含むギャップマーオリゴヌクレオチド
|
|
EP3728590B1
(en)
|
2017-12-22 |
2025-07-02 |
Roche Innovation Center Copenhagen A/S |
Novel thiophosphoramidites
|
|
KR102617947B1
(ko)
|
2017-12-29 |
2023-12-27 |
쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 |
접합체와 제조 및 그 용도
|
|
CN111699258A
(zh)
|
2018-01-10 |
2020-09-22 |
哥本哈根罗氏创新中心 |
用于调控pias4表达的寡核苷酸
|
|
JP7547201B2
(ja)
|
2018-01-12 |
2024-09-09 |
ブリストル－マイヤーズ スクイブ カンパニー |
アルファ－シヌクレインを標的とするアンチセンスオリゴヌクレオチドおよびその使用
|
|
MY203356A
(en)
|
2018-01-12 |
2024-06-25 |
Bristol Myers Squibb Co |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
|
EP3737760A1
(en)
|
2018-01-12 |
2020-11-18 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating gsk3b expression
|
|
PE20210172A1
(es)
*
|
2018-01-12 |
2021-01-29 |
Roche Innovation Ct Copenhagen As |
Oligonucleotidos antisentido para alfa-sinucleina y usos de los mismos
|
|
WO2019140452A1
(en)
|
2018-01-15 |
2019-07-18 |
Ionis Pharmaceuticals, Inc. |
Modulators of dnm2 expression
|
|
EP3740574A1
(en)
|
2018-01-17 |
2020-11-25 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating erc1 expression
|
|
JP2021511029A
(ja)
|
2018-01-18 |
2021-05-06 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Ｓｒｅｂｐ１を標的とするアンチセンスオリゴヌクレオチド
|
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
|
MX2020005751A
(es)
*
|
2018-01-26 |
2020-08-20 |
Hoffmann La Roche |
Oligonucleotidos radioetiquetados y proceso para su preparacion.
|
|
BR112020016170A2
(pt)
|
2018-02-09 |
2020-12-15 |
Genentech, Inc. |
Oligonucleotídeos terapêutico e antissenso, conjugado, sal farmaceuticamente aceitável, composição farmacêutica, método in vitro ou in vivo para modular a expressão de tmem106b, método para tratar ou prevenir uma doença, uso do oligonucleotídeo e uso ou método
|
|
CN112020559A
(zh)
|
2018-02-21 |
2020-12-01 |
百时美施贵宝公司 |
Camk2d反义寡核苷酸及其用途
|
|
TWI840345B
(zh)
|
2018-03-02 |
2024-05-01 |
美商Ionis製藥公司 |
Irf4表現之調節劑
|
|
WO2019169243A1
(en)
|
2018-03-02 |
2019-09-06 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-beta precursor protein
|
|
CN115976028B
(zh)
|
2018-03-09 |
2025-03-25 |
第一三共株式会社 |
糖原病Ia型治疗药
|
|
EP3768694A4
(en)
|
2018-03-22 |
2021-12-29 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating fmr1 expression
|
|
CR20200453A
(es)
|
2018-04-05 |
2021-03-02 |
Centre Leon Berard |
Uso de inhibidores de fubp1 para el tratamiento de infección de virús de hepatitis b
|
|
KR20200141481A
(ko)
|
2018-04-11 |
2020-12-18 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Ezh2 발현의 조절제
|
|
WO2019215065A1
(en)
|
2018-05-07 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Massively parallel discovery methods for oligonucleotide therapeutics
|
|
WO2019215175A1
(en)
|
2018-05-08 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
EP3790972A1
(en)
|
2018-05-08 |
2021-03-17 |
Regulus Therapeutics Inc. |
Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
|
|
CA3098144A1
(en)
|
2018-05-09 |
2019-11-14 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing atxn3 expression
|
|
BR112020020957B1
(pt)
|
2018-05-09 |
2022-05-10 |
Ionis Pharmaceuticals, Inc |
Compostos oligoméricos, população e composição farmacêutica dos mesmos e seus usos
|
|
TWI844541B
(zh)
|
2018-05-11 |
2024-06-11 |
新加坡商波濤生命科學有限公司 |
寡核苷酸組成物及其使用方法
|
|
BR112020022620A2
(pt)
*
|
2018-05-11 |
2021-02-17 |
Alpha Anomeric Sas |
conjugados de oligonucleotídeos que compreendem nucleosídeos de açúcar 7'-5'-alfa-anomérico-bicíclicos
|
|
GB201808146D0
(en)
|
2018-05-18 |
2018-07-11 |
Proqr Therapeutics Ii Bv |
Stereospecific Linkages in RNA Editing Oligonucleotides
|
|
JP7379387B2
(ja)
|
2018-06-05 |
2023-11-14 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ａｔｘｎ２発現を制御するためのオリゴヌクレオチド
|
|
WO2019241648A1
(en)
|
2018-06-14 |
2019-12-19 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing stmn2 expression
|
|
TWI833770B
(zh)
|
2018-06-27 |
2024-03-01 |
美商Ionis製藥公司 |
用於減少 lrrk2 表現之化合物及方法
|
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
|
BR112020026973A2
(pt)
|
2018-07-03 |
2021-04-06 |
F. Hoffmann-La Roche Ag |
Oligonucleotídeos para modulação da expressão tau
|
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
|
MX2021000404A
(es)
|
2018-07-13 |
2021-03-25 |
Hoffmann La Roche |
Oligonucleotidos para modular la expresion de rtel1.
|
|
WO2020018558A1
(en)
|
2018-07-17 |
2020-01-23 |
Aronora, Inc. |
Methods for safely reducing thrombopoietin
|
|
EP3826645A4
(en)
|
2018-07-25 |
2023-05-17 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR REDUCING ATXN2 EXPRESSION
|
|
EP3830101B1
(en)
*
|
2018-07-31 |
2025-11-19 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
|
KR20210040060A
(ko)
|
2018-07-31 |
2021-04-12 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
포스포로트리티오에이트 뉴클레오시드간 연쇄를 포함하는 올리고뉴클레오티드
|
|
AU2019316640A1
(en)
|
2018-08-10 |
2021-03-18 |
University Of Massachusetts |
Modified oligonucleotides targeting SNPs
|
|
CN111655849B
(zh)
|
2018-08-21 |
2024-05-10 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的药物组合物和缀合物及其用途
|
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
|
EP3840759A4
(en)
|
2018-08-23 |
2022-06-01 |
University Of Massachusetts |
O-METHYL RICH FULLY STABILIZED OLIGONUCLEOTIDES
|
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
|
CN112585280A
(zh)
|
2018-08-23 |
2021-03-30 |
罗氏创新中心哥本哈根有限公司 |
微小rna-134生物标志物
|
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
|
EP3844274A1
(en)
|
2018-08-28 |
2021-07-07 |
Roche Innovation Center Copenhagen A/S |
Neoantigen engineering using splice modulating compounds
|
|
EP3620519A1
(en)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
|
|
US20220056443A1
(en)
*
|
2018-09-06 |
2022-02-24 |
Aptamir Therapeutics, Inc. |
Metabolic benefits of short mir-22 mirna antagomir therapies
|
|
CN111655297A
(zh)
|
2018-09-30 |
2020-09-11 |
苏州瑞博生物技术有限公司 |
一种siRNA缀合物及其制备方法和用途
|
|
JP2022512877A
(ja)
|
2018-11-01 |
2022-02-07 |
エフ．ホフマン－ラ ロシュ アーゲー |
Ｔｉａ１を標的とするアンチセンスオリゴヌクレオチド
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
WO2020102630A1
(en)
|
2018-11-15 |
2020-05-22 |
Ionis Pharmaceuticals, Inc. |
Modulators of irf5 expression
|
|
BR112021007476A2
(pt)
|
2018-11-21 |
2021-11-03 |
Ionis Pharmaceuticals Inc |
Compostos e métodos para reduzir a expressão de príon
|
|
EP3894559A4
(en)
|
2018-12-03 |
2023-04-05 |
Triplet Therapeutics, Inc. |
METHODS OF TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS RELATED TO MLH3 ACTIVITY
|
|
JP2022515744A
(ja)
|
2018-12-20 |
2022-02-22 |
プラクシス プレシジョン メディシンズ， インコーポレイテッド |
Ｋｃｎｔ１関連障害の治療のための組成物及び方法
|
|
WO2020136125A2
(en)
|
2018-12-21 |
2020-07-02 |
Boehringer Ingelheim International Gmbh |
Antisense oligonucleotides targeting card9
|
|
JP7507495B2
(ja)
|
2018-12-28 |
2024-06-28 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
|
|
AU2020207935A1
(en)
|
2019-01-18 |
2021-08-26 |
University Of Massachusetts |
Dynamic pharmacokinetic-modifying anchors
|
|
WO2020152303A1
(en)
|
2019-01-25 |
2020-07-30 |
F. Hoffmann-La Roche Ag |
Lipid vesicle for oral drug delivery
|
|
EP3917540A1
(en)
|
2019-01-31 |
2021-12-08 |
Ionis Pharmaceuticals, Inc. |
Modulators of yap1 expression
|
|
EP3927716A1
(en)
|
2019-02-20 |
2021-12-29 |
Roche Innovation Center Copenhagen A/S |
Novel phosphoramidites
|
|
WO2020169695A1
(en)
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Phosphonoacetate gapmer oligonucleotides
|
|
WO2020173845A1
(en)
|
2019-02-26 |
2020-09-03 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide formulation method
|
|
CA3131700A1
(en)
|
2019-02-27 |
2020-09-03 |
Ionis Pharmaceuticals, Inc. |
Modulators of malat1 expression
|
|
JP2022522898A
(ja)
*
|
2019-03-05 |
2022-04-20 |
エフ．ホフマン－ラ ロシュ アーゲー |
分子の細胞内標的化
|
|
HUE071494T2
(hu)
|
2019-03-29 |
2025-09-28 |
Ionis Pharmaceuticals Inc |
Vegyületek és eljárások az UBE3A-ATS modulálására
|
|
EP3947678A1
(en)
|
2019-04-02 |
2022-02-09 |
ProQR Therapeutics II B.V. |
Antisense oligonucleotides for immunotherapy
|
|
JP7725370B2
(ja)
|
2019-04-03 |
2025-08-19 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用
|
|
CN113785060A
(zh)
|
2019-04-04 |
2021-12-10 |
豪夫迈·罗氏有限公司 |
用于调节atxn2表达的寡核苷酸
|
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
|
EP3974532A4
(en)
|
2019-05-22 |
2024-01-24 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PROCESS OF PREPARATION AND USE
|
|
EP3974530A4
(en)
|
2019-05-22 |
2023-07-12 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, METHOD FOR PREPARATION AND USE
|
|
KR20220024192A
(ko)
|
2019-05-31 |
2022-03-03 |
알리고스 테라퓨틱스 인코포레이티드 |
변형된 갭머 올리고뉴클레오타이드 및 사용 방법
|
|
WO2020245233A1
(en)
|
2019-06-06 |
2020-12-10 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
|
EP3956450B1
(en)
|
2019-07-26 |
2025-08-13 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
|
CN114466929A
(zh)
*
|
2019-07-30 |
2022-05-10 |
Mpeg La有限责任公司 |
具有增强的生物活性的多聚体寡核苷酸的皮下递送
|
|
WO2021030213A1
(en)
|
2019-08-09 |
2021-02-18 |
University Of Massachusetts |
Chemically modified oligonucleotides targeting snps
|
|
WO2021049504A1
(ja)
|
2019-09-10 |
2021-03-18 |
第一三共株式会社 |
肝臓送達用ＧａｌＮＡｃ－オリゴヌクレオチドコンジュゲートおよび製造方法
|
|
US12365894B2
(en)
|
2019-09-16 |
2025-07-22 |
University Of Massachusetts |
Branched lipid conjugates of siRNA for specific tissue delivery
|
|
CN115315514B
(zh)
*
|
2019-10-02 |
2025-11-21 |
圣诺制药公司 |
具有核苷类似物的寡核苷酸
|
|
JP2023506540A
(ja)
|
2019-12-19 |
2023-02-16 |
エフ． ホフマン－ラ ロシュ エージー． |
Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用
|
|
EP4058032A4
(en)
*
|
2019-12-19 |
2024-01-10 |
Entrada Therapeutics, Inc. |
Compositions for delivery of antisense compounds
|
|
CN115516091A
(zh)
|
2019-12-19 |
2022-12-23 |
豪夫迈·罗氏有限公司 |
Cops3抑制剂用于治疗乙型肝炎病毒感染的用途
|
|
CN114829601A
(zh)
|
2019-12-19 |
2022-07-29 |
豪夫迈·罗氏有限公司 |
Sbds抑制剂用于治疗乙型肝炎病毒感染的用途
|
|
CN114867856A
(zh)
|
2019-12-19 |
2022-08-05 |
豪夫迈·罗氏有限公司 |
Saraf抑制剂用于治疗乙型肝炎病毒感染的用途
|
|
JP7634542B2
(ja)
|
2019-12-19 |
2025-02-21 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用
|
|
AR120817A1
(es)
|
2019-12-20 |
2022-03-23 |
Hoffmann La Roche |
Oligonucleótidos mejorados para inhibir la expresión de scn9a
|
|
CN114828852A
(zh)
|
2019-12-24 |
2022-07-29 |
豪夫迈·罗氏有限公司 |
用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合
|
|
CA3163490A1
(en)
|
2019-12-24 |
2021-07-01 |
F. Hoffman-La Roche Ag |
Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
|
|
US20230090446A1
(en)
|
2020-01-28 |
2023-03-23 |
Universite De Strasbourg |
Antisense oligonucleotide targeting linc00518 for treating melanoma
|
|
WO2021158810A1
(en)
|
2020-02-05 |
2021-08-12 |
Bristol-Myers Squibb Company |
Oligonucleotides for splice modulation of camk2d
|
|
JP2023516142A
(ja)
|
2020-02-28 |
2023-04-18 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｃｄ７３エクソン７スプライシングを調節するためのオリゴヌクレオチド
|
|
IL295605A
(en)
|
2020-02-28 |
2022-10-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating smn2
|
|
WO2021178725A1
(en)
*
|
2020-03-04 |
2021-09-10 |
Verve Therapeutics, Inc. |
Compositions and methods for targeted rna delivery
|
|
TW202144572A
(zh)
|
2020-03-19 |
2021-12-01 |
美商亞維代堤生物科學公司 |
治療臉肩胛肱骨肌肉失養症之組合物及方法
|
|
JP2023522961A
(ja)
*
|
2020-04-21 |
2023-06-01 |
フラッグシップ パイオニアリング， インコーポレイテッド |
二機能性分子およびその使用方法
|
|
BR112022021333A2
(pt)
|
2020-05-01 |
2022-12-13 |
Ionis Pharmaceuticals Inc |
Compostos e métodos para modular atxn1
|
|
JP2023527693A
(ja)
|
2020-05-11 |
2023-06-30 |
ジェネンテック， インコーポレイテッド |
神経疾患を治療するための補体成分ｃ１ｒ阻害剤、並びに関連する組成物、システム、及びそれを使用する方法
|
|
EP4150084A1
(en)
|
2020-05-11 |
2023-03-22 |
Genentech, Inc. |
Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
|
|
EP4149486A1
(en)
|
2020-05-11 |
2023-03-22 |
Genentech, Inc. |
Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
|
|
EP4150083A1
(en)
|
2020-05-13 |
2023-03-22 |
F. Hoffmann-La Roche AG |
Oligonucleotide agonists targeting progranulin
|
|
EP4150088A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
|
WO2021231680A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
|
EP4150089A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
|
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
|
EP4150077A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
|
JP2023526096A
(ja)
|
2020-05-22 |
2023-06-20 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｃａｒｄ９のスプライス調節のためのオリゴヌクレオチド
|
|
WO2021242883A1
(en)
|
2020-05-26 |
2021-12-02 |
University Of Massachusetts |
Synthetic oligonucleotides having regions of block and cluster modifications
|
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
|
US20230212572A1
(en)
|
2020-06-09 |
2023-07-06 |
Roche Innovation Center Copenhagen A/S |
Guanosine Analogues for Use in Therapeutics Polynucleotides
|
|
AR122731A1
(es)
|
2020-06-26 |
2022-10-05 |
Hoffmann La Roche |
Oligonucleótidos mejorados para modular la expresión de fubp1
|
|
MX2022016338A
(es)
|
2020-06-29 |
2023-01-24 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular la plp1.
|
|
WO2022018155A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotides for splice modulation of stmn2
|
|
WO2022018187A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Oligonucleotides targeting rna binding protein sites
|
|
MX2023001222A
(es)
|
2020-07-28 |
2023-04-26 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para reducir la expresion de app.
|
|
CN111671913B
(zh)
*
|
2020-07-30 |
2022-02-08 |
四川大学 |
一种量子点-小核酸偶联物及其用途
|
|
MX2023001486A
(es)
|
2020-08-07 |
2023-03-27 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular scn2a.
|
|
JP2023538630A
(ja)
|
2020-08-21 |
2023-09-08 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用
|
|
EP4196102A1
(en)
*
|
2020-10-02 |
2023-06-21 |
Sirnaomics, Inc. |
NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES
|
|
EP4488371A3
(en)
|
2020-11-18 |
2025-04-09 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
|
US20230060373A1
(en)
|
2020-12-03 |
2023-03-02 |
Hoffmann-La Roche Inc. |
Antisense Oligonucleotides Targeting ATXN3
|
|
US20220177883A1
(en)
|
2020-12-03 |
2022-06-09 |
Hoffmann-La Roche Inc. |
Antisense Oligonucleotides Targeting ATXN3
|
|
IL303800A
(en)
|
2020-12-18 |
2023-08-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating factor xii
|
|
CN116583603A
(zh)
|
2020-12-18 |
2023-08-11 |
豪夫迈·罗氏有限公司 |
靶向颗粒蛋白前体的反义寡核苷酸
|
|
WO2022136140A1
(en)
|
2020-12-22 |
2022-06-30 |
F. Hoffmann-La Roche Ag |
Oligonucleotides targeting xbp1
|
|
CN114716518A
(zh)
*
|
2021-01-06 |
2022-07-08 |
圣诺制药公司 |
一种能够抑制pcsk9表达的分子构造及药物组合物
|
|
EP4284513A1
(en)
|
2021-01-26 |
2023-12-06 |
Universite Brest Bretagne Occidentale |
Novel stim1 splicing variants and uses thereof
|
|
TW202246500A
(zh)
|
2021-02-02 |
2022-12-01 |
瑞士商赫孚孟拉羅股份公司 |
用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸
|
|
MX2023010535A
(es)
|
2021-03-08 |
2023-09-19 |
Servier Lab |
Oligonucleotidos antisentido para inhibir la expresion de la alfa-sinucleina.
|
|
WO2022232650A1
(en)
*
|
2021-04-30 |
2022-11-03 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing agt expression
|
|
US20240263177A1
(en)
|
2021-05-20 |
2024-08-08 |
Korro Bio, Inc. |
Methods and Compositions for Adar-Mediated Editing
|
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
|
AU2022288115A1
(en)
|
2021-06-08 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Oligonucleotide progranulin agonists
|
|
US12378267B2
(en)
|
2021-06-17 |
2025-08-05 |
Entrada Therapeutics, Inc. |
Synthesis of FMOC-protected morpholino monomers and oligomers
|
|
BR112023026050A2
(pt)
|
2021-06-18 |
2024-03-05 |
Ionis Pharmaceuticals Inc |
Compostos e métodos para reduzir expressão de ifnar1
|
|
MX2023015523A
(es)
|
2021-06-23 |
2024-03-11 |
Univ Massachusetts |
Compuestos de oligonucleotidos anti-flt1 optimizados para el tratamiento de la preeclampsia y otros desordenes angiogenicos.
|
|
EP4363574A1
(en)
|
2021-06-29 |
2024-05-08 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
|
WO2023034561A2
(en)
*
|
2021-09-02 |
2023-03-09 |
Vanderbilt University |
Lipophilic oligonucleotide conjugates
|
|
CA3231330A1
(en)
|
2021-09-16 |
2023-03-23 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
|
US20250352667A1
(en)
|
2021-10-22 |
2025-11-20 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
|
WO2023078883A1
(en)
|
2021-11-03 |
2023-05-11 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating apolipoprotein e4 expression
|
|
CN118284695A
(zh)
|
2021-11-11 |
2024-07-02 |
豪夫迈·罗氏有限公司 |
用于治疗hbv的药物组合
|
|
JP2025501682A
(ja)
*
|
2021-12-03 |
2025-01-23 |
クラリス コーポレーション |
改変された骨格化学を有するギャップマーアンチセンスオリゴヌクレオチド
|
|
EP4444882A1
(en)
|
2021-12-07 |
2024-10-16 |
F. Hoffmann-La Roche AG |
Antisense oligonucleotides targeting actl6b
|
|
CN119095603A
(zh)
|
2021-12-17 |
2024-12-06 |
豪夫迈·罗氏有限公司 |
用于调节rtel1和fubp1的寡核苷酸的组合
|
|
JP2024546887A
(ja)
|
2021-12-17 |
2024-12-26 |
ジェネンテック， インコーポレイテッド |
オリゴヌクレオチドｇｂａアゴニスト
|
|
JP2024547071A
(ja)
|
2021-12-20 |
2024-12-26 |
エフ． ホフマン－ラ ロシュ アーゲー |
トレオース核酸アンチセンスオリゴヌクレオチドおよびその方法
|
|
EP4465994A1
(en)
|
2022-01-20 |
2024-11-27 |
Genentech, Inc. |
Antisense oligonucleotides for modulating tmem106b expression
|
|
AR128558A1
(es)
|
2022-02-21 |
2024-05-22 |
Hoffmann La Roche |
Oligonucleótido antisentido
|
|
WO2023176863A1
(ja)
|
2022-03-16 |
2023-09-21 |
第一三共株式会社 |
ＲＮＡｉ活性を有する化学修飾オリゴヌクレオチド
|
|
TW202345867A
(zh)
|
2022-03-16 |
2023-12-01 |
日商第一三共股份有限公司 |
抑制運鐵蛋白受體2表現的siRNA
|
|
WO2023217890A1
(en)
|
2022-05-10 |
2023-11-16 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting cfp-elk1 intergene region
|
|
EP4526445A1
(en)
|
2022-05-18 |
2025-03-26 |
F. Hoffmann-La Roche AG |
Improved oligonucleotides targeting rna binding protein sites
|
|
EP4282964A1
(en)
*
|
2022-05-23 |
2023-11-29 |
Universitat de Valéncia |
Oligonucleotides conjugated to oleic acid and uses thereof
|
|
EP4540386A1
(en)
|
2022-06-17 |
2025-04-23 |
F. Hoffmann-La Roche AG |
Antisense oligonucleotides for targeting progranulin
|
|
EP4332221A1
(en)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
|
AU2023337487A1
(en)
|
2022-09-06 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Double-stranded rna molecule for administration to the eye
|
|
WO2024064858A2
(en)
|
2022-09-23 |
2024-03-28 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing mecp2 expression
|
|
WO2024112809A2
(en)
*
|
2022-11-21 |
2024-05-30 |
Pepgen Inc. |
Cell-penetrating peptides, conjugates thereof, and methods of their use
|
|
WO2024126654A1
(en)
|
2022-12-14 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting actl6b
|
|
EP4652273A1
(en)
|
2023-01-16 |
2025-11-26 |
Institut National de la Recherche pour l'Agriculture, l'Alimentation et l'Environnement |
Antisense molecules and their uses for the treatment of coronavirus infection, in particular the treatment of covid-19 related to sars-cov-2 infection
|
|
EP4652262A1
(en)
|
2023-01-19 |
2025-11-26 |
Altos Labs, Inc. |
Use of regeneration factors in organ transplantation
|
|
WO2024196893A1
(en)
*
|
2023-03-17 |
2024-09-26 |
Camford Labs Inc. |
Chemically modified nucleotides
|
|
EP4689116A1
(en)
*
|
2023-03-30 |
2026-02-11 |
Ractigen Therapeutics |
Vehicles for delivering oligonucleotides and methods of use thereof
|
|
CN121263524A
(zh)
|
2023-05-04 |
2026-01-02 |
豪夫迈·罗氏有限公司 |
能够上调葡糖脑苷脂酶表达的寡核苷酸
|
|
TW202508607A
(zh)
*
|
2023-05-19 |
2025-03-01 |
大陸商北京炫景瑞醫藥科技有限公司 |
雙股寡核苷酸及其共軛物和用途
|
|
AR132975A1
(es)
|
2023-06-16 |
2025-08-13 |
Hoffmann La Roche |
Oligonucleótidos bicatenarios para modular la expresión de jak1
|
|
WO2025036916A1
(en)
|
2023-08-16 |
2025-02-20 |
Les Laboratoires Servier |
Oligonucleotides for modulating kcnt1 expression
|
|
WO2026006436A1
(en)
|
2024-06-25 |
2026-01-02 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
|
|
WO2026024954A2
(en)
|
2024-07-24 |
2026-01-29 |
Altos Labs, Inc. |
Use of regeneration factors in organ transplantation
|